Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

With the improvement in CT scanners and injectors, diagnostic chest CT can now be performed in less than 10 seconds. It was hypothesized that diagnostic CT pulmonary angiograms could be done with less than the usual 80-120 ml of contrast used. We have developed a method of performing diagnostic CT pulmonary angiograms with 30 ml of intravenous contrast in most patients. The long-term objective of this study is to show that there is no difference in the diagnostic efficacy of this low dose 30 ml technique when compared to the more traditional full-dose technique.

Condition or disease	Intervention/treatment	Phase
Multiple Pulmonary Emboli	Procedure: Low-Dose IV Contrast; Device: Siemens Sensation 64-MDCT scanner.; Drug: Visipaque 320 non-ionic isoosmolar contrast agent	Not Applicable

Detailed Description:

Potential participants in the study will have been referred to the radiology section for a CTPA for a suspected pulmonary embolus. The radiologist will review the patient's record in CPRS, as is done routinely in this situation. Patients with class 3 or 4 CHF, supraventricular tachycardia, Serum Creatinine >1.5 mg/dl (>1.3 mg/dl female), history of contrast allergy, or unable to give informed consent will be excluded from both arms of the study. Patients with serum creatinine >1.28 mg/dl require referring physician approval. If the participant appears to qualify for the study then the study physician will contact the referring physician and inform him/her of the study. If the referring physician is agreeable then either the radiologist or the referring physician will approach the patient, either at the bedside or in the radiology clinic to determine if the patient is interested in participating in the study. If so, a study radiologist will begin the informed consent process. After informed consent is obtained the subject will be computer randomized to either the new low-dose or full-dose technique protocols. A total of 220 studies (110 per group) will be performed.

Multidetector CT Scan: All CT examinations will be performed on the Siemens Sensation 64-MDCT scanner. Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be used in all contrast examinations followed by a subsequent injection of normal saline. An informed written consent for the injection of IV contrast will be obtained prior to all CT examinations. Safe venous access will be obtained via either an antecubital vein or a central venous line. For low dose CT pulmonary angiograms, 30 ml of IV Radio Contrast Material (RCM) will be injected at a flow rate of 5 ml/second followed by an injection of 20 ml of normal saline at 5ml/second. The region of interest (ROI) will be the superior vena cava (SVC) at the approximate level of the aortic arch. The scan will be triggered to begin at 75 Hounsfield units (HU). For Full dose CT pulmonary angiograms, 100 ml of IV RCM will be injected at a flow rate of 5ml/sec. The ROI will be the main pulmonary artery. The scan will be triggered at 120 HU. One mm contiguous axial spiral scans will be obtained from the apex of the lung through the adrenals. Reformatted 1.5 mm axial, 3 mm axial, 1.5 mm coronal and sagittal images will be obtained. All images will be uploaded to the AGFA Picture Archiving Communication System (PACS) workstation for interpretation. The costs of all CT scans and RCM will be covered by the Department of Imaging as the majority of the studies are part of routine clinical care.

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	0 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Single (Outcomes Assessor)
Primary Purpose:	Diagnostic
Official Title:	Efficacy Of Low(30 Ml) Versus Full Dose (100 Ml)Contrast CT Pulmonary Angiography Performed On 64 Multi-Detector CT In Detecting Emboli
Study Start Date :	January 2016
Estimated Primary Completion Date :	December 2017
Estimated Study Completion Date :	December 2018

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Low-Dose IV Contrast; A single intravenous dose of 30 ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.	Procedure: Low-Dose IV Contrast; A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.; Other Names: Visipaque; Iodixanol Device: Siemens Sensation 64-MDCT scanner.; The device will be used to perform CT Pulmonary Angiograms Drug: Visipaque 320 non-ionic isoosmolar contrast agent; Single Dose of Intravenous Iodixanol will be administered per CT scan.; Other Name: Iodixanol
Active Comparator: Full-Dose IV Contrast; A single intravenous dose of 100ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.	Procedure: Low-Dose IV Contrast; A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.; Other Names: Visipaque; Iodixanol Device: Siemens Sensation 64-MDCT scanner.; The device will be used to perform CT Pulmonary Angiograms Drug: Visipaque 320 non-ionic isoosmolar contrast agent; Single Dose of Intravenous Iodixanol will be administered per CT scan.; Other Name: Iodixanol

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. CT Image Quality Score [ Time Frame: Within 4 weeks of the CT scan ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Patients referred for CT pulmonary angiogram to exclude pulmonary embolus

Exclusion Criteria:

• Class 3 or 4 Congestive Heart Failure
• Supraventricular tachycardia
• History of contrast allergy
• Unable to give informed consent
• Patients with serum creatinine >1.28 mg/dl without referring physician approval

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, California
VALosAngeles
Los Angeles, California, United States, 90073

Sponsors and Collaborators

VA Greater Los Angeles Healthcare System

Investigators

Principal Investigator:	Bruce M. Barack, M.D.	VA Greater Los Angeles Healthcare System

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Bruce Barack, Staff Radiologist, VA Greater Los Angeles Healthcare System
ClinicalTrials.gov Identifier:	NCT01935141 History of Changes
Other Study ID Numbers:	2012-101526
First Posted:	September 4, 2013
Last Update Posted:	November 8, 2016
Last Verified:	November 2016

Keywords provided by Bruce Barack, VA Greater Los Angeles Healthcare System:

Pulmonary Embolus; Radio Contrast Material; Computed Tomography

Additional relevant MeSH terms:

Embolism; Pulmonary Embolism; Embolism and Thrombosis; Vascular Diseases	Cardiovascular Diseases; Lung Diseases; Respiratory Tract Diseases